Condition
Multiple Sclerosis, Acute Relapsing
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01442233Phase 3Completed
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
NCT04546698CompletedPrimary
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
NCT02398461Phase 1CompletedPrimary
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
Showing all 3 trials